跳至主要内容
临床试验/NCT02304627
NCT02304627已完成1 期

Effect of Food on the Pharmacokinetics of NNC0123-0000-0338 in a Tablet Formulation in Healthy Subjects

Novo Nordisk A/S1 个研究点 分布在 1 个国家目标入组 45 人开始时间: 2014年11月24日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
1 期
状态
已完成
入组人数
45
试验地点
1
主要终点
Area under the serum insulin 338 concentration-time curve

研究概览

简要总结

This trial is conducted in Europe. The aim of the trial is to investigate the effect of food on the pharmacokinetics (the exposure of the trial drug in the body) of NNC0123-0000-0338 in a tablet formulation in healthy subjects.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Crossover
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 64 Years(Adult)
性别
Male
接受健康志愿者

入选标准

  • Age 18-64 years (both inclusive) at the time of signing informed consent
  • Body mass index 18.5-28.0 kg/m^2 (both inclusive)
  • Subject who is considered to be healthy based on the medical history, physical examination, and the results of vital signs, electrocardiogram and clinical laboratory tests performed during the screening visit, as judged by the investigator

排除标准

  • Known or suspected hypersensitivity to trial products or related products
  • Previous participation in this trial. Participation is defined as informed consent
  • Presence of clinically significant acute and chronic gastrointestinal symptoms (e.g. nausea, vomiting, heartburn or diarrhoea) within 2 weeks prior to first dosing, as judged by the investigator

研究组 & 干预措施

Eating meal immediately after dosing

Experimental

干预措施: insulin 338 (GIPET I) (Drug)

Eating meal 30 min after dosing

Experimental

干预措施: insulin 338 (GIPET I) (Drug)

Eating meal 1 hour after dosing

Experimental

干预措施: insulin 338 (GIPET I) (Drug)

Eating meal 6 hour after dosing

Experimental

干预措施: insulin 338 (GIPET I) (Drug)

结局指标

主要结局

Area under the serum insulin 338 concentration-time curve

时间窗: From a 0-288 hours NNC0123-0000-0338 serum concentration-time-curve based on 41 sampling time points

次要结局

  • Area under the serum insulin 338 concentration-time curve(From 0 to 288 hours after a single dose (SD))
  • Maximum observed serum insulin 338 concentration(From 0 to 288 hours after a single dose (SD))
  • Area under the plasma capric acid concentration-time curve(From 0 to 24 hours after a single dose)
  • Maximum observed plasma capric acid concentration(From 0 to 24 hours after a single dose)

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验